Cancer Biological Therapy Market - By Application (Diagnostic Laboratories, Hospitals, Pharmaceutical & Biotechnology Companies, And Research & Academic Laboratories), By Product (Vaccines {Therapeutic Vaccines And Preventive Vaccines}, Monoclonal Antibodies { Conjugated Monoclonal Antibodies, Naked Monoclonal Antibodies, And Bispecific Monoclonal Antibodies}, Blood Cell Growth Factors {Filgrastim And Lenograstim}, Cancer Growth Blockers { Proteasome Inhibitors, Tyrosine Kinase Inhibitors, And mTOR Inhibitors}, Cytokine { Interleukin And Interferon}), And By Region - Global Industry Perspective, Comprehensive Analysis, and Forecast, 2020 – 2026

Description

The global cancer biological therapy market was estimated at 74.36 (USD Billion) in 2019 and set to record a CAGR of nearly 6.7% over 2020-2026. The report offers valuation and analysis of cancer biological therapy market on a global as well as regional level. The study offers a comprehensive assessment of the industry competition, limitations, sales estimates, avenues, current & emerging trends, and industry-validated market data. The report offers historical data from 2016 to 2018 along with a forecast from 2019 to 2025 based on value (USD Billion).

Introduction

Biological therapy or biotherapy is a new cancer treatment method. It makes use of biological response modifiers as well as biologicals for treating cancer. Moreover, these substances originate from mammalian cells and improves the immune response. Additionally, launching of molecular biological procedures and hybridoma technology has resulted in preparation of these substances in huge quantities and highly pure form to apply them in cancer biological therapy.  Additionally, nanomedicine provides a tool of biocompatible systems that can provide traditional chemotherapeutic medicines in vivo along with raising their bioavailability around the cancerous tumors and increasing their release profile. Reportedly, nanoparticles can be used for oncology applications that range from diagnosis to treatment.

Market Growth Dynamics

Cancer is one of the key causes of deaths across the globe and in the last few years a large number of research studies have demonstrated the necessity of introducing new treatments for reducing the side effects due to traditional therapies and this will drive the market trends. Apparently, biological therapies like oncolytic virus therapy and immunotherapy are well tolerated by the bodies of the patients and have low side-effects as compared to chemotherapies due to its effective immune tolerance mechanisms. This will help the market scale up new terrains of growth over the forecast timespan.

Furthermore, rise in the incurrence of cancer, surging impact of biosimilars, and escalating need for targeted drug treatments will steer the expansion of the market over the forthcoming years. Huge funding of cancer research projects and government aid for developing new cancer treatments will amplify the growth rate of the market in the years to come.

North America To Contribute Majorly Towards Overall Industry Share Over 2020-2026

The growth of the market over the forecast timeline is owing to massive cases of cancer witnessed in the countries like the U.S. In addition to this, increase in the proportion of aging populace prone to chronic ailments like cancer will help the regional market reach new milestones of growth in the forthcoming years.

Key players profiled in the market are Spectrum Pharmaceuticals, Amgen, F. Hoffmann-La Roche, AbbVie, AstraZeneca, Novartis, Astellas, Pfizer, Celgene Corporation, Sanofi, Takeda Pharmaceuticals, Bayer, ELI Lilly & Company, Eisai, GlaxoSmithKline, Merck, Incyte, Otsuka, and Seattle Genetics.

The global cancer biological therapy market is segmented as follows:

By product type

• Monoclonal Antibodies
  • Naked Monoclonal Antibodies
  • Conjugated Monoclonal Antibodies
  • Bispecific Monoclonal Antibodies
• Vaccines
  • Preventive Vaccines
  • Therapeutic Vaccines
• Cancer Growth Blockers
  • Tyrosine Kinase Inhibitors
  • Proteasome Inhibitors
  • mTOR Inhibitors
• Blood Cell Growth Factors
  • Lenograstim
  • Filgrastim
• Cytokine
  • Interferon
  • Interleukin

By Application:

• Hospitals
• Diagnostic Laboratories
• Research & Academic Laboratories
• Pharmaceutical & Biotechnology Companies

By Region

• North America
  • The U.S.
  • Canada
• Europe
  • France
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • South Africa
  • Rest of Middle East & Africa

Table Of Content

• Chapter 1. Preface
  • 1.1. Report Description and Scope
  • 1.2. Research Scope
  • 1.3. Research Methodology
    • 1.3.1. Market Research Process
    • 1.3.2. Market Research Methodology
• Chapter 2. Executive Summary
  • 2.1. Cancer Biulogical Therapy Market , 2016–2026 (USD Billion)
  • 2.2. Cancer Biulogical Therapy Market : Snapshot
• Chapter 3. Global Cancer Biulogical Therapy Market – Industry Analysis
  • 3.1. Cancer Biulogical Therapy Market : Market Dynamics
  • 3.2. Market Drivers
    • 3.2.1. Rise in the incurrence of cancer, surging impact of biosimilars, and escalating need for targeted drug treatments will steer the expansion of the market over the forthcoming years.
    • 3.2.2. Huge funding of cancer research projects and government aid for developing new cancer treatments will amplify the growth rate of the market in the years to come.
  • 3.3. Porter’s Five Forces Analysis
  • 3.4. Market Attractiveness Analysis
    • 3.4.1. Market attractiveness analysis By Application
    • 3.4.2. Market attractiveness analysis By Product
• Chapter 4. Global Cancer Biulogical Therapy Market – Competitive Landscape
  • 4.1. Company market share analysis
    • 4.1.1. Global Cancer Biulogical Therapy Market : company market share, 2018
  • 4.2. Strategic development
    • 4.2.1. Acquisitions & mergers
    • 4.2.2. New Vehicle launches
    • 4.2.3. Agreements, partnerships, cullaborations, and joint ventures
    • 4.2.4. Research and development and Regional expansion
  • 4.3. Price trend analysis
• Chapter 5. Global Cancer Biulogical Therapy Market – Application Analysis
  • 5.1. Global Cancer Biulogical Therapy Market overview: By Application
    • 5.1.1. Global Cancer Biulogical Therapy Market share, By Application , 2019 and 2026
  • 5.2. Diagnostic Laboratories
    • 5.2.1. Global Cancer Biulogical Therapy Market By Diagnostic Laboratories, 2016–2026 (USD Billion)
  • 5.3. Hospitals
    • 5.3.1. Global Cancer Biulogical Therapy Market By Hospitals, 2016–2026 (USD Billion)
  • 5.4. Pharmaceutical & Biotechnulogy Companies
    • 5.4.1. Global Cancer Biulogical Therapy Market By Pharmaceutical & Biotechnulogy Companies, 2016–2026 (USD Billion)
  • 5.5. Research & Academic Laboratories
    • 5.5.1. Global Cancer Biulogical Therapy Market By Research & Academic Laboratories, 2016–2026 (USD Billion)
• Chapter 6. Global Cancer Biulogical Therapy Market – Product Analysis
  • 6.1. Global Cancer Biulogical Therapy Market overview: By Product
    • 6.1.1. Global Cancer Biulogical Therapy Market share, By Product, 2019 and 2026
  • 6.2. Monoclonal Antibodies
    • 6.2.1. Global Cancer Biulogical Therapy Market By Monoclonal Antibodies, 2016–2026 (USD Billion)
  • 6.3. Vaccines
    • 6.3.1. Global Cancer Biulogical Therapy Market By Vaccines, 2016–2026 (USD Billion)
  • 6.4. Cancer Growth Blockers
    • 6.4.1. Global Cancer Biulogical Therapy Market By Cancer Growth Blockers, 2016–2026 (USD Billion)
  • 6.5. Blood Cell Growth Factors
    • 6.5.1. Global Cancer Biulogical Therapy Market By Blood Cell Growth Factors, 2016–2026 (USD Billion)
  • 6.6. Cytokine
    • 6.6.1. Global Cancer Biulogical Therapy Market By Cytokine, 2016–2026 (USD Billion)
• Chapter 7. Company Profiles
  • 7.1. Spectrum Pharmaceuticals
    • 7.1.1. Overview
    • 7.1.2. Financials
    • 7.1.3. Product Portfolio
    • 7.1.4. Business Strategy
    • 7.1.5. Recent Developments
  • 7.2. Amgen
    • 7.2.1. Overview
    • 7.2.2. Financials
    • 7.2.3. Product Portfolio
    • 7.2.4. Business Strategy
    • 7.2.5. Recent Developments
  • 7.3. F. Hoffmann-La Roche
    • 7.3.1. Overview
    • 7.3.2. Financials
    • 7.3.3. Product Portfolio
    • 7.3.4. Business Strategy
    • 7.3.5. Recent Developments
  • 7.4. AbbVie
    • 7.4.1. Overview
    • 7.4.2. Financials
    • 7.4.3. Product Portfolio
    • 7.4.4. Business Strategy
    • 7.4.5. Recent Developments
  • 7.5. AstraZeneca
    • 7.5.1. Overview
    • 7.5.2. Financials
    • 7.5.3. Product Portfolio
    • 7.5.4. Business Strategy
    • 7.5.5. Recent Development
  • 7.6. Novartis
    • 7.6.1. Overview
    • 7.6.2. Financials
    • 7.6.3. Product Portfolio
    • 7.6.4. Business Strategy
    • 7.6.5. Recent Development
  • 7.7. Astellas
    • 7.7.1. Overview
    • 7.7.2. Financials
    • 7.7.3. Product Portfolio
    • 7.7.4. Business Strategy
    • 7.7.5. Recent Development
  • 7.8. Pfizer
    • 7.8.1. Overview
    • 7.8.2. Financials
    • 7.8.3. Product Portfolio
    • 7.8.4. Business Strategy
    • 7.8.5. Recent Development
  • 7.9. Celgene Corporation
    • 7.9.1. Overview
    • 7.9.2. Financials
    • 7.9.3. Product Portfolio
    • 7.9.4. Business Strategy
    • 7.9.5. Recent Development
  • 7.10. Sanofi
    • 7.10.1. Overview
    • 7.10.2. Financials
    • 7.10.3. Product Portfolio
    • 7.10.4. Business Strategy
    • 7.10.5. Recent Development
  • 7.11. Takeda Pharmaceuticals
    • 7.11.1. Overview
    • 7.11.2. Financials
    • 7.11.3. Product Portfolio
    • 7.11.4. Business Strategy
    • 7.11.5. Recent Development
  • 7.12. Bayer
    • 7.12.1. Overview
    • 7.12.2. Financials
    • 7.12.3. Product Portfolio
    • 7.12.4. Business Strategy
    • 7.12.5. Recent Development
  • 7.13. ELI Lilly & Company
    • 7.13.1. Overview
    • 7.13.2. Financials
    • 7.13.3. Product Portfolio
    • 7.13.4. Business Strategy
    • 7.13.5. Recent Development
  • 7.14. Eisai
    • 7.14.1. Overview
    • 7.14.2. Financials
    • 7.14.3. Product Portfolio
    • 7.14.4. Business Strategy
    • 7.14.5. Recent Development
  • 7.15. GlaxoSmithKline
    • 7.15.1. Overview
    • 7.15.2. Financials
    • 7.15.3. Product Portfolio
    • 7.15.4. Business Strategy
    • 7.15.5. Recent Development
  • 7.16. Merck
    • 7.16.1. Overview
    • 7.16.2. Financials
    • 7.16.3. Product Portfolio
    • 7.16.4. Business Strategy
    • 7.16.5. Recent Development
  • 7.17. Incyte
    • 7.17.1. Overview
    • 7.17.2. Financials
    • 7.17.3. Product Portfolio
    • 7.17.4. Business Strategy
    • 7.17.5. Recent Development
  • 7.18. Otsuka
    • 7.18.1. Overview
    • 7.18.2. Financials
    • 7.18.3. Product Portfolio
    • 7.18.4. Business Strategy
    • 7.18.5. Recent Development
  • 7.19. Seattle Genetics
    • 7.19.1. Overview
    • 7.19.2. Financials
    • 7.19.3. Product Portfolio
    • 7.19.4. Business Strategy
    • 7.19.5. Recent Development

Methodology